Insmed (INSM) Competitors $109.30 -1.96 (-1.76%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$110.23 +0.93 (+0.85%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. GSK, TAK, ARGX, ONC, BNTX, SMMT, TEVA, GMAB, MRNA, and RDYShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Insmed vs. Its Competitors GSK Takeda Pharmaceutical argenex BeOne Medicines BioNTech Summit Therapeutics Teva Pharmaceutical Industries Genmab A/S Moderna Dr. Reddy's Laboratories GSK (NYSE:GSK) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Do analysts prefer GSK or INSM? GSK currently has a consensus target price of $37.38, indicating a potential downside of 0.59%. Insmed has a consensus target price of $109.20, indicating a potential downside of 0.09%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 1 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.88Insmed 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GSK or INSM more profitable? GSK has a net margin of 10.81% compared to Insmed's net margin of -265.93%. GSK's return on equity of 49.22% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets GSK10.81% 49.22% 11.31% Insmed -265.93%-446.98%-52.70% Which has preferable earnings and valuation, GSK or INSM? GSK has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGSK$40.10B1.91$3.29B$2.1617.41Insmed$381.03M54.42-$913.77M-$5.95-18.37 Does the media prefer GSK or INSM? In the previous week, GSK had 7 more articles in the media than Insmed. MarketBeat recorded 18 mentions for GSK and 11 mentions for Insmed. GSK's average media sentiment score of 0.56 beat Insmed's score of 0.36 indicating that GSK is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Insmed 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, GSK or INSM? GSK has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Do institutionals and insiders have more ownership in GSK or INSM? 15.7% of GSK shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 3.0% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryGSK beats Insmed on 11 of the 16 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.11B$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.18%P/E Ratio-18.3717.9729.8725.14Price / Sales54.42262.19422.9397.17Price / CashN/A41.8335.9458.58Price / Book68.317.238.105.59Net Income-$913.77M-$54.43M$3.26B$265.48M7 Day Performance0.56%0.22%0.64%1.22%1 Month Performance13.69%5.59%2.42%0.39%1 Year Performance52.21%9.98%27.60%23.47% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed3.6473 of 5 stars$109.30-1.8%$109.20-0.1%+54.0%$21.11B$381.03M-18.371,271Earnings ReportGap DownGSKGSK2.586 of 5 stars$37.49-1.3%$37.38-0.3%-4.5%$76.76B$31.53B19.3268,629TAKTakeda Pharmaceutical2.5229 of 5 stars$14.31-1.2%N/A+4.1%$45.53B$30.09B65.0547,455High Trading VolumeARGXargenex4.1148 of 5 stars$595.19+0.5%$728.06+22.3%+35.2%$36.43B$2.58B36.721,599ONCBeOne Medicines1.3153 of 5 stars$294.51+1.0%$327.56+11.2%N/A$32.28B$3.81B-79.1711,000Trending NewsEarnings ReportAnalyst ForecastInsider TradeBNTXBioNTech1.9799 of 5 stars$112.79-2.2%$136.58+21.1%+40.5%$27.11B$2.98B-33.176,772Earnings ReportAnalyst ForecastSMMTSummit Therapeutics2.0679 of 5 stars$27.45-4.3%$34.67+26.3%+198.6%$20.39B$700K-80.73110Positive NewsOptions VolumeTEVATeva Pharmaceutical Industries2.9369 of 5 stars$16.53-0.1%$24.71+49.5%-2.8%$18.96B$16.62B-14.3736,830Positive NewsInsider TradeGMABGenmab A/S3.6707 of 5 stars$23.09-1.3%$37.80+63.7%-14.2%$14.81B$3.12B13.122,682News CoverageShort Interest ↑MRNAModerna4.3276 of 5 stars$33.91-0.7%$46.11+36.0%-67.4%$13.11B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst RevisionRDYDr. Reddy's Laboratories2.3432 of 5 stars$14.71+0.2%$16.95+15.3%-17.7%$12.28B$3.81B22.2827,811 Related Companies and Tools Related Companies GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors BioNTech Competitors Summit Therapeutics Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
